RECRUITING

SPECT/CT for the Characterization of Renal Masses

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This trial studies how well technetium Tc-99m sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) works on clinical decision making in patients with kidney tumors. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT/CT may be a less invasive way to check for kidney tumors.

Official Title

SPECT/CT for the Characterization of Renal Masses: Impact on Clinical Decision Making

Quick Facts

Study Start:2018-12-07

Study Completion:2025-12-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT03996850

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Performance status Eastern Cooperative Oncology Group (ECOG) \< 2. * Life expectancy (\> 1 year). * New diagnosis of a renal tumor (within past 3 months). * Measurable, predominantly (\> 80%) solid renal neoplasm between 1.5-5.0 cm. * Lesion concerning for kidney cancer bases on a contrast-enhanced CT or magnetic resonance imaging (MRI). * No definitive evidence of metastatic disease. * Does not require urgent surgical treatment. * Candidate for surgical, ablative, and surveillance approach. * Willingness to obtain more information to aid decision-making. * Understanding and willingness to provide consent.	* Presence of multiple solid renal tumors. * A prior needle biopsy of the mass resulting in histologic diagnosis. * A prior diagnosis of kidney cancer. * Presence of an active, untreated, non-renal malignancy. * History of bleeding diathesis or recent bleeding episode. * Prior surgery or radiation therapy to the kidney. * Unwillingness to fill out questionnaires.

Inclusion Criteria

Exclusion Criteria

* Performance status Eastern Cooperative Oncology Group (ECOG) \< 2.
* Life expectancy (\> 1 year).
* New diagnosis of a renal tumor (within past 3 months).
* Measurable, predominantly (\> 80%) solid renal neoplasm between 1.5-5.0 cm.
* Lesion concerning for kidney cancer bases on a contrast-enhanced CT or magnetic resonance imaging (MRI).
* No definitive evidence of metastatic disease.
* Does not require urgent surgical treatment.
* Candidate for surgical, ablative, and surveillance approach.
* Willingness to obtain more information to aid decision-making.
* Understanding and willingness to provide consent.

* Presence of multiple solid renal tumors.
* A prior needle biopsy of the mass resulting in histologic diagnosis.
* A prior diagnosis of kidney cancer.
* Presence of an active, untreated, non-renal malignancy.
* History of bleeding diathesis or recent bleeding episode.
* Prior surgery or radiation therapy to the kidney.
* Unwillingness to fill out questionnaires.

Contacts and Locations

Principal Investigator

Brian Shuch

PRINCIPAL_INVESTIGATOR

UCLA / Jonsson Comprehensive Cancer Center

Study Locations (Sites)

UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, 90095

United States

Collaborators and Investigators

Sponsor: Jonsson Comprehensive Cancer Center

Brian Shuch, PRINCIPAL_INVESTIGATOR, UCLA / Jonsson Comprehensive Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2018-12-07

Study Completion Date2025-12-31

Study Record Updates

Study Start Date2018-12-07

Study Completion Date2025-12-31

Terms related to this study

Additional Relevant MeSH Terms

Kidney Neoplasm
Renal Mass